Zevra Therapeutics (ZVRA) Q2 2025 Earnings
How Did ZVRA Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +2.48%.
Did ZVRA Beat Earnings? Q2 2025 Results
No. Zevra Therapeutics reported Q2 2025 earnings of $1.21 a share on Aug 12, 2025, missing the $1.38 consensus estimate by 12.4%. Revenue was $25.9M against a $26.6M estimate.
Zevra Therapeutics delivered a headline-grabbing but ultimately mixed second quarter, with a $150 million Priority Review Voucher sale reshaping its financials even as the company fell short on both top and bottom lines. Reported GAAP earnings came in at $1.21 per diluted share, missing the $1.38 consensus by 12.40%, while revenue of $25.88 million trailed the $26.64 million estimate by 2.86%, though the figure still represented a striking 481.7% increase year over year as MIPLYFFA's commercial ramp gained traction. The most consequential development beneath the surface was a $58.71 million non-cash impairment of intangible assets tied to OLPRUVA, reflecting weak enrollment trends and competitive pressures that dulled an otherwise pivotal quarter. MIPLYFFA contributed $21.50 million in net product revenue, adding 7 new prescription enrollment forms and reaching 52% covered lives. Analysts trimmed price targets modestly following the results while maintaining constructive ratings, and management projected confidence in its strategic runway, backed by a $217.70 million cash position and a recently submitted EMA marketing application for arimoclomol in Niemann-Pick disease type C.
- MIPLYFFA U.S. launch driving product revenue growth, with 129 cumulative prescription enrollment forms
- PRV sale generated $148.3 million in net proceeds, driving reported net income
- Market access for MIPLYFFA reached 52% of covered lives
- Market access for OLPRUVA increased to 79% of covered lives
- R&D expense decreased $7.1 million due to KP1077 Phase 2 trial completion
“This is an exciting time of growth for Zevra. Following approval late last year, we are focused on executing the U.S. launch of MIPLYFFA®, and we believe the remarkable performance in the second quarter sets a strong foundation for continued momentum. As the only treatment that has been shown to halt disease progression by addressing its underlying pathology, we are invigorated by the meaningful impact MIPLYFFA is bringing to people diagnosed with Niemann-Pick disease type C (NPC). Now, with the recent submission of the Marketing Authorisation Application (MAA) in the E.U., we seek to expand these differentiated benefits to greater numbers of patients with this debilitating disease.”
Zevra Therapeutics CEO, on the earnings call
What Was Zevra Therapeutics's Outlook in Q2 2025?
Zevra believes the strong Q2 2025 MIPLYFFA performance sets a foundation for continued momentum. The company submitted the MAA to the EMA for arimoclomol in NPC, meeting H2 2025 guidance, seeking European market expansion. Management stated the company has sufficient resources and financial flexibility to execute on strategic priorities independent from capital markets, supported by the $217.7 million cash position following the PRV sale.
ZVRA YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $25.9M | $4.4M | +481.7% |
| Net Income | $74.7M | $13.0M | +474.9% |
ZVRA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.